Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
May 01 2024 - 12:13PM
Business Wire
Affini-T Therapeutics, Inc., a precision immunotherapy company
unlocking the power of T cells against oncogenic driver mutations,
today announced that data from its preclinical gene edited
HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell
Receptor (TCR) T cell therapy products for the treatment of solid
cancers will be presented at the American Society of Gene &
Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May
7-11.
“Our mission is to address the significant unmet needs of
patients with hard-to-treat solid tumors by advancing precision
immunotherapies that target oncogenic driver mutations,” said Loïc
Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics.
“We believe that our non-viral targeted knock-in platform,
THRIVETM, will enable us to cost-effectively engineer safe and
effective T cell therapy products. We look forward to presenting
new data showing that THRIVETM-engineered A11 KRAS G12D-targeting
TCR T cells (AFNT-212) and TP53 R175H-targeting TCR T cells
demonstrated superior cytotoxicity against tumor cells relative to
LVV-engineered cells both in vitro and in vivo, at ASGCT this
year.”
Affini-T also announced that data from a genomic profiling
dataset illustrating the low frequency of HLA loss of
heterozygosity in cancer patients will be presented at ASGCT.
“TCR based therapies targeting cancer driver mutations recognize
the human leukocyte antigen (HLA)/peptide complex on tumor cells,”
said Dirk Nagorsen, M.D., Chief Medical Officer at Affini-T
Therapeutics. “In this context, loss of heterozygosity (LOH) of HLA
may be of interest but only in cases when the specific HLA allele
that is presenting the targeted peptide is involved. Conversely,
historical allele-agnostic HLA-LOH analyses, which assessed the
loss of any MHC class I allele, would only be relevant in the
setting of HLA-agnostic therapies, e.g., immune checkpoint
inhibitors. We look forward to presenting data showing that the
allele-specific HLA-LOH frequency is low, which suggests that
allele-specific HLA-LOH frequency is unlikely to contribute
significantly to clinical data readouts of TCR-based
therapies.”
Poster presentation details are as follows:
Title: THRIVE TM Non-Viral Targeted Transgene Knock-In
Platform Generates Specific and Potent TCR T Cell Products for the
Treatment of Solid Cancers Abstract #836, Session: G2
- Immune Targeting and Approaches with Genetically-Modified Cells
and Cell Therapies Session Date/Time: Wednesday, May 8,
2024, 12:00 PM – 7:00 PM Presenting Author: Ankit Gupta,
Ph.D., Senior Director, Gene Editing, Discovery, Affini-T
Therapeutics
Title: Loss of Heterozygosity is Low for Specific HLA
Alleles in Cancer Patients with Driver Mutations Abstract
#785, Session: F3 - Cancer – Targeted Gene and Cell
Therapy Session Date/Time: Wednesday, May 8, 2024, 12:00 PM
– 7:00 PM Presenting Author: Christian Roy, Ph.D., Associate
Director, Precision and Translational Medicine, Affini-T
Therapeutics
About Affini-T Therapeutics
Affini-T is a leading precision immunotherapy company targeting
oncogenic driver mutations, beginning with KRAS, to develop
potentially curative therapies for patients with solid tumors. We
are advancing two distinct therapeutic modalities encompassing
adoptive cellular therapies and bispecific T cell engagers, each
designed to harness T cell immunity with unprecedented precision
and potency against solid tumors. Our TCR-T cell therapy-enabling
platforms utilize state-of-the-art engineering, synthetic biology,
and gene editing capabilities to rewrite the rules of the tumor
microenvironment and optimize T cell functions. Our bispecific T
cell engager platform combines high throughput affinity maturation
TCR discovery and biologics format constructions to target
oncogenic driver mutations. Building on the world-class innovation
inherent in our leadership team, founders, and technologies, we are
powered to develop transformational medicines that last. For more
information, visit affinittx.com and follow us on LinkedIn and X,
formerly known as Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501955728/en/
Media Contact Danielle Cantey Inizio Evoke
danielle.cantey@inizioevoke.com 619-826-4657
Investor Contact IR@affinittx.com